Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OS Therapies IncOSTX · Entity 6950 | Director · President and CEO | December 31, 2024 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OS Therapies Inc
Report date December 31, 2024 · Filed May 15, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 | Direct | 500,000 |
Reported balance
After 2024-12-05 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2024-12-05 · Grant · Acquired 500,000 · Balance 500,000 F1: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 500,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | Direct | 2,248,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 2,248,000 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 500,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Feb 13, 2026 21:41 UTC | OS Therapies Inc OSTX · Entity 6950 | GrantStock options (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001213900-26-016497 · ownership.xml · derivative · entry 2 Romness Paul A. · CIK 0001974517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2036-01-22 F1 · derivative.exercise_date: On January 22, 2026, the reporting person was granted options to purchase 1,000,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date. Read SEC document |
| October 21, 2025 Filed Dec 19, 2025 23:31 UTC | OS Therapies Inc OSTX · Entity 6950 | GrantStock options (right to buy) · Derivative | 1,950,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001213900-25-123998 · ownership.xml · derivative · entry 2 Romness Paul A. · CIK 0001974517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,950,000 Underlying: Common Stock · 1,950,000 shares Expires 2035-10-21 F1 · derivative.exercise_date: On October 21, 2025, the reporting person was granted options to purchase 1,950,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date. Read SEC document |
| October 21, 2025 Filed Feb 13, 2026 21:20 UTC Amendment | OS Therapies Inc OSTX · Entity 6950 | GrantStock options (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001213900-26-016435 · ownership.xml · derivative · entry 2 Romness Paul A. · CIK 0001974517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2035-10-21 F1 · derivative.exercise_date: On October 21, 2025, the reporting person was granted options to purchase 1,000,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 23:03 UTC | OS Therapies Inc OSTX · Entity 6950 | OtherCommon Stock, par value $0.001 per share | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-018889 · ownership.xml · nonDerivative · entry 1 Romness Paul A. · CIK 0001974517 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,473,000 F1 · price: Pursuant to a Transfer Agreement, effective as of May 13, 2024 (the "Transfer Agreement"), between Einodmil LLC ("Einodmil") and the reporting person, 600,000 shares of the issuer's common stock owned by the reporting person were placed in escrow in exchange for Einodmil's participation in a pre-IPO lock-up agreement. The Transfer Agreement, entered into in connection with the issuer's initial public offering, outlined conditions for distributing the 600,000 shares after expiration of the lock-up period, based on the 20-day VWAP of the issuer's common stock. On February 28, 2025, 225,000 of these shares were released from escrow and transferred to the reporting person. The remaining 375,000 shares were released from escrow and transferred to Einodmil. Read SEC document |
| December 05, 2024 Filed Feb 14, 2025 21:25 UTC | OS Therapies Inc OSTX · Entity 6950 | GrantNon-qualified stock options (right to buy) · Derivative | 800,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0000921895-25-000497 · form513679001rom_02142025.xml · derivative · entry 2 Romness Paul A. · CIK 0001974517 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common stock, par value $0.001 per share · 800,000 shares Expires not disclosed F1 · derivative.exercise_date: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 800,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions. F1 · derivative.expiration_date: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 800,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions. Read SEC document |
| December 05, 2024 Filed May 15, 2026 22:30 UTC Amendment | OS Therapies Inc OSTX · Entity 6950 | GrantNon-qualified stock options (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001213900-26-058022 · ownership.xml · derivative · entry 2 Romness Paul A. · CIK 0001974517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common stock, par value $0.001 per share · 500,000 shares Expires not disclosed F1 · derivative.exercise_date: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 500,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions. F1 · derivative.expiration_date: On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 500,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.